AMRX (Amneal Pharmaceuticals) Net Income From Continuing Operations : $-146 Mil (TTM As of Sep. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Amneal Pharmaceuticals's net income from continuing operations for the three months ended in Sep. 2024 was $12 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was $-146 Mil.

Amneal Pharmaceuticals Net Income From Continuing Operations Historical Data

The historical data trend for Amneal Pharmaceuticals's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amneal Pharmaceuticals Net Income From Continuing Operations Chart

Amneal Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

-603.57

68.58

20.17

-254.79

-48.72

Amneal Pharmaceuticals Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income From Continuing Operations	Get a 7-Day Free Trial															25.03	-93.34	-81.68	16.79	11.76

Amneal Pharmaceuticals Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-146 Mil.

Amneal Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

2DT:Germany

Address

400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807

Website

https://www.amneal.com

Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.

Executives

Gautam Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Deborah M. Autor	director	C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
John Kiely	director	C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Jason B. Daly	officer: SVP, Chief Legal Officer	400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Andrew S Boyer	officer: Exec VP, Comm Optns	C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Nikita Shah	officer: SVP, Chief HR Officer	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tpg Gp A, Llc	10 percent owner	301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin	officer: See Remarks	4 PARK LANE, MADISON NJ 07940
Jon Winkelried	10 percent owner	C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Chirag K. Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel	director	C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco	officer: SVP, Specialty Commercial	400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George	director	C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Shlomo Yanai	director	ONE MEADOWLANDS PLAZA, EAST RUTHERFORD NJ 07073
Paul M Meister	director	18 SHIP ROCK ROAD, NORTH HAMPTON NH 03862